Abstract:Background The UGT1A1*28 polymorphism, although closely linked with CPT-11-related adverse effects, cannot be used alone to guide individualized treatment decisions. However, CPT-11 dosage can be adjusted according to measured SN-38 pharmacokinetics. Our study is designed to investigate whether there is a relationship between SN-38 peak or valley concentrations and efficacy or adverse effects of CPT-11-based chemotherapy. We retrospectively studied 98 patients treated with advanced colorectal cancer in various UGT1A1*28 genotype groups (mainly (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes) treated with CPT-11 as first-line chemotherapy in Shanghai. Methods One hundred and sixty-four advanced colorectal cancer patients were enrolled. To understand differences in genotype expression, the frequency of UGT1A1*28 thymine–adenine (TA) repeats in TATA box arrangement was assessed by PCR with genomic DNA extracted from peripheral blood. For ninety-eight cases with the (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes treated with CPT-11 as first-line chemotherapy, the plasma concentration of SN-38 was detected by HPLC 1.5 and 49 h after CPT-11 infusion. Efficacy and adverse effects were observed subsequently, and the relationship between SN-38 plasma concentration and efficacy or adverse effects within genotype groups, as well as differences in efficacy and adverse effects between (TA) 6 /(TA) 6 and (TA) 6 /(TA) 7 genotypes were analyzed statistically. Results One hundred and fourteen patients (69.51 %) were identified with the (TA) 6 /(TA) 6 genotype, forty-eight patients (29.27 %) with the (TA) 6 /(TA) 7 genotype, and two patients (1.22 %) with the (TA) 7 /(TA) 7 genotype. The average peak and valley concentrations of SN-38 after CPT-11 infusion and plasma bilirubin average levels before and after CPT-11 treatment in the (TA) 6 /(TA) 7 genotype group were all higher than those in (TA) 6 /(TA) 6 group, and the difference was statistically significant ( p = 0.00). Stepwise regression analysis showed that SN-38 peak and valley concentration was correlated with PFS in the (TA) 6 /(TA) 6 genotype. In the (TA) 6 /(TA) 7 group, SN-38 peak concentration was correlated with CPT-11 starting dose and OS, valley concentration correlated with plasma bilirubin levels before CPT-11 treatment, delayed diarrhea, and OS. For the (TA) 6 /(TA) 6 genotype, mPFS of the SN-38 peak concentration >43.2 ng/ml subgroup was significantly longer than that of ≤43.2 ng/ml subgroup (8.0 ± 0.35 vs. 6.5 ± 0.79 months, χ 2 = 17.18, p = 0.00) with a relatively high incidence of Grade I/II° myelosuppression; for the (TA) 6 /(TA) 7 genotype, there was no significant difference in mOS between the SN-38 valley concentration >16.83 ng/ml and ≤16.83 subgroups (17.3 ± 0.45 vs. 18.8 ± 0.50 months, χ 2 = 1.38, p = 0.24), but the former had a higher incidence of Grade III/IV° mucositis and delayed diarrhea. For 2 (TA) 7 /(TA) 7 cases, although 25 % dose reduction of CPT-11, which is calculated according to body surface area, Grade IV° bone marrow suppression and Grade III° delayed diarrhea still occurred after CPT-11 treatment, though both adverse effects resolved and did not recur again after a 50 % dose reduction. Conclusion The (TA) 6 /(TA) 6 genotype and (TA) 6 /(TA) 7 genotype accounted for the most, and (TA) 7 /(TA) 7 genotype only account for a very small portion of advanced colorectal cancer patients in Shanghai. For the (TA) 6 /(TA) 6 genotype, CPT-11 dosage can be increased gradually to improve efficacy for patients with SN-38 peak concentration ≤43.2 ng/ml after CPT-11 infusion; and for (TA) 6 /(TA) 7 genotype patients, CPT-11 dosage may be lowered appropriately to reduce serious adverse effects such as bone marrow suppression and delayed diarrhea without affecting the efficacy for those with SN-38 valley concentration >16.83 ng/ml. For (TA) 7 /(TA) 7 genotype patients, adverse effects should be closely observed after treatment even if CPT-11 dosage has been reduced.

UGT1A1 Genotype-Guided Irinotecan Dosing During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Prospective Analysis of SN-38 Concentration

Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

[Polymorphisms of UGT1A Gene and Irinotecan Toxicity in Chinese Colorectal Cancer Patients].

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai

Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer

Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer

An Expansion Study of Genotype-Driven Weekly Irinotecan and Capecitabine in Combination with Neoadjuvant Radiotherapy for Locally Advanced Rectal Cancer with UGT1A1 11 Genotype

Relationship between UGT1A1 gene polymorphisms and toxicity of irinotecan-based chemotherapy ;in colorectal cancer

The Influence of Functional Polymorphisms in Ugt1a7 and Ugt1a9 on Irinotecan Pharmacokinetics in Asian Cancer Patients.

Clinical Study of the Correlation between UGT1A1 Polymorphism and the Safety and Efficacy of Irinotecan

Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

Relationship between UGT1A16/28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer

Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer

UGT1A1 6/28 Polymorphisms Could Predict Irinotecan-Induced Severe Neutropenia Not Diarrhea in Chinese Colorectal Cancer Patients.

Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations

Predictive Value of UGT1A1*28 Polymorphism in Irinotecan-based Chemotherapy

Multicentre Randomised Phase III Trial of Capecitabine with or Without Irinotecan Guided by UGT1A1 Status in Patients Undergoing Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer